Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Rosenstock J, Frias J, Jastreboff AM, et al. The Lancet 2023;402:529-544.
What it found
At 24 weeks, HbA1c fell by up to 2.02% (12 mg) vs 0.01% with placebo and 1.41% with dulaglutide. At 36 weeks, weight fell by up to about 17% on the 8 mg and 12 mg doses vs 3.0% on placebo and 2.0% on dulaglutide. Gastrointestinal events were reported by 35% on retatrutide overall, up to 50% in one 8 mg group.
Limitations
Phase 2: some dose groups had only 23 to 26 people. US sites only.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.